Navigation Links
Shire plc: Strong Third Quarter and Increased Non GAAP Earnings Expectations
Date:10/24/2013

on now in place, Shire has a more effective process to evaluate holistically all pipeline opportunities as well as business development prospects. Our pipeline has been prioritized to focus on development programs that have the best chance of clinical and commercial success together with early stage research in rare diseases. We believe that these measures will ensure Shire is optimally positioned to enable the continued development of products that serve unmet patient need and to sustain the track record of high growth.

OUTLOOK


We are increasing our guidance to mid-to-high teens Non GAAP earnings growth for the full year in 2013 (previous guidance: double digit Non GAAP earnings growth) as we continue to see operating costs benefit from our reorganization efforts.

We anticipate a similar level of product sales growth in the fourth quarter as we delivered in the third quarter, and continue to expect full year product sales growth in the mid-to-high single digits.

We continue to expect royalties and other revenues to be 35-40% lower than 2012.

Our Non GAAP gross margin for the full year is expected to remain at a similar level to 2012.

With investment prioritized behind our promising pipeline and our late stage clinical trials, we now expect Non GAAP R&D to be 5-7% higher for the full year than in 2012 (previous guidance: growth in the low double digits).

Non GAAP SG&A for the full year is now anticipated to be 5-7% lower than 2012 (previous guidance: 2-4% lower). Non GAAP SG&A in the fourth quarter is expected to be slightly higher than in the third quarter as we provide targeted support to our commercial team to invest behind our key products.

As a result, we now expect combined Non GAAP R&D and SG&A to be 1-3% lower than 2012 (previous guidance: only marginally higher). This translates to a reduced spend of $250 million compared with our guidance forecasts in February 2013['/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
6. Shire Changes its NASDAQ Ticker Symbol to SHPG
7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Shire Reaches Agreement in Principle With U.S. Government
10. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
11. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 Marianjoy Rehabilitation Hospital ... arm and hand impairments by acquiring the Armeo®Spring ... Terrace network site. , Secured through grant support ... highly-regarded treatment option for patients with upper extremity ... becomes one of just four Illinois providers offering ...
(Date:5/1/2015)... Md. , May 1, 2015  Northwest Biotherapeutics ... company developing DCVax® personalized immune therapies for solid tumor ... the $28.5 million second tranche of a $40 million ... Woodford first invested $25 million in NW ... Woodford entered into an agreement with the Company for ...
(Date:5/1/2015)... N.C. (PRWEB) May 01, 2015 ... Charlotte (UNC Charlotte) spin-out company, announced that Pinku Mukherjee, ... the UNC Board of Governors’ highest faculty honor. ... to humanity’s welfare , for her innovative research and ... Max Gardner Award represents a crowning moment in my ...
(Date:5/1/2015)... MN , May 1, 2015 /PRNewswire/ - BioAmber ... producing sustainable chemicals, today announced that it has priced an ... stock at a price of $9.00 per share, and ... to purchase up to an additional 585,000 shares of ... will be $35.1 million.  The offering is expected to close ...
Breaking Biology Technology:Marianjoy Acquires Armeo®Spring Arm and Hand Rehabilitation Exoskeleton at Oakbrook Terrace Facility 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 3OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3
... fighting to stay on budget as the first quarter of 2009 came to ... a field once thought immune to the troubles of the rest of the ... ... March 23, 2009 -- As the first quarter of 2009 came to a ...
... Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN ... its SCORPION(TM) multispecific therapeutic technology at the 100th ... Research (AACR) in Denver. The data presented demonstrated ... CD79BxDR SCORPION molecule, its differentiation from monospecific approaches, ...
... Do winery tasting rooms really help generate sales for ... Innovation Centre almost half of winery tasting room visitors ... visit. , "This research proves that the tasting room ... in future sales," said Dr. Isabelle Lesschaeve, research director, ...
Cached Biology Technology:The MedZilla Report: March 2009 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: March 2009 Employment Outlook for Biotech/Pharma/Health 3The MedZilla Report: March 2009 Employment Outlook for Biotech/Pharma/Health 4Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting 2Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting 3Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting 4Setting the Benchmark for Winery Tasting Room Research: An Emerging Region Gets a Global Perspective 2
(Date:4/27/2015)... , April 27, 2015  For more than ... trade show has been the premier worldwide event for ... 2015 is a must-attend event for any local, national, ... into the emerging commercial markets and current applications of ... innovations of this projected $48 billion industry, and how ...
(Date:4/27/2015)... , Apr. 27, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... to pre-order customers the first week of May, 2015 ... month of May. Gino Pereira ... milestone for the company as Wocket® enters the consumer ...
(Date:4/27/2015)... FORT LAUDERDALE, Fla. , Apr. 27, 2015 /PRNewswire/ ... provider of access control and security systems is pleased ... joined the company as a consultant and member of ... Bedore is widely known as a thought leader ... Socrates Distance Learning Technology Group, and has published studies ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... 2010) Healthy pre-and post-menopausal Japanese women who ... a novel soy germ-based ingredient under development for ... reproductive hormones that stayed within normal limits throughout ... at the American Medical Women,s Association (AMWA) 2010 ...
... inhabited the southern coast of Scandinavia 4,000 years ago ... new study carried out by researchers at Uppsala University ... in the journal BMC Evolutionary Biology , supports ... descended from the Stone Age people in question but ...
... of the zebra finch genome, a new resource has ... thematic series published by BioMed Central, the open access ... As part of the series, a study published in ... related to steroid receptors and estrogen biosynthesis. Researchers writing ...
Cached Biology News:Soy germ-based supplement SE5-OH containing natural S-Equol examined for safety, hormonal influence 2Soy germ-based supplement SE5-OH containing natural S-Equol examined for safety, hormonal influence 3Soy germ-based supplement SE5-OH containing natural S-Equol examined for safety, hormonal influence 4Stone Age Scandinavians unable to digest milk 2
Request Info...
Request Info...
Prepared by multi-temperature ethanol fractionation with extensive charcoal treatment and dialysis.• Assay: ≥ 95 % (HPCE)• pH ~5.2 (10 mg/mL in 0.15 M NaCl)...
Special grade: for electrophoresis...
Biology Products: